Skip to main content
Fig. 2 | Clinical Proteomics

Fig. 2

From: A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer

Fig. 2

Representative mass spectra, scatter plot and ROC (Receiver Operating Characteristic) curve analysis of top four most prominently different expression of glycoforms between non-metastatic GC patients and GC patients with peritoneal metastasis. a 2620.93 m/z (H6N5L1E1). b 2650.98 m/z (H5N5F1E2). c 2666.96 m/z (H6N5E2). d 2940.08 m/z (H6N5L1E2) were identified. GC gastric cancer, PM peritoneal metastasis, AUC area under ROC curve, H hexose, N N-acetylhexosamine, F fucose, L α 2,3-sialic acid, E α 2,6-sialic acid. ***P < 0.001

Back to article page

Clinical Proteomics

ISSN: 1559-0275